drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous chimeric antigen receptor T cells engineered to target glypican-3 (GPC3), enabling MHC-independent recognition and killing of GPC3-positive tumor cells; infused after lymphodepleting chemotherapy.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor targeting glypican‑3 (GPC3) bind GPC3 on tumor cells independent of MHC, triggering T‑cell activation, cytokine release, and cytotoxic killing of GPC3‑positive cancer cells; infused after lymphodepleting chemotherapy to enhance expansion and persistence.
drug_name
IM83 CAR-T cells
nct_id_drug_ref
NCT06412458